# MVM Partners

MVM Partners is a Private Equity based in London, United Kingdom.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** 38 Wigmore Street, London, W1U 2RU, United Kingdom
- **Founded:** 1997
- **Assets under management:** > $1 billion (Altss estimate)
- **Website:** www.mvm.com
- **LinkedIn:** https://www.linkedin.com/company/mvm-partnersllp

## Regulatory record

- **CRD number:** 159224
- **SEC file number:** 802-74677
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/159224

## About

Founded in 1997 by a team of healthcare investment specialists, MVM Partners operates from London, Boston, and the San Francisco Bay Area. The firm was purpose-built for healthcare, not as a generalist fund that drifted into the sector, and its longevity—over two decades—has outlasted most specialist peers. MVM does not trace its capital to a single wealthy family or a large institutional anchor seeded for diversification purposes. MVM pursues growth-stage and expansion-stage investments across the healthcare and life-sciences spectrum, from medical devices and pharmaceuticals to diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing. The firm typically commits $20 million to $100 million in equity per company and has a track record that includes both acquisitions and initial public offerings. Confirmed active portfolio companies include Axonics, a medical device developer, and Paragon 28, a foot-and-ankle orthopedic company. MVM invests primarily in North America and Europe, with a focus on products that demonstrate a durable competitive moat through intellectual property, regulatory exclusivity, or unique branding. The firm maintains offices in London, Boston, and the San Francisco Bay Area. MVM does not publicly disclose its current fund vehicles, nor does it list a specific roster of investment professionals by name. The firm does not operate a public-facing philanthropic foundation and has not characterized itself as a multi-family office or co-investment club. MVM is structured as a pure-play healthcare private equity firm that spans both venture and later-stage financing, a dual posture that distinguishes it from early-stage-only venture firms or large-cap generalist buyout shops. A management team may tap MVM for minority growth capital with the same platform that can later lead a take-private or a buyout, creating a single-relationship capital stack that can follow a company from commercial validation through exit. This hybrid structure is less common in life sciences, where funding pathways typically require a handoff from venture investors to crossover funds or large strategics.

## Sectors

- Healthcare Services
- Digital Health
- Medical Devices
- Pharmaceuticals
- Diagnostics
- Life Science Tools

## Offices

- Boston, MA
- San Francisco Bay Area, CA

## Questions

### How does MVM Partners distinguish itself from pure venture capital firms?

MVM operates a hybrid strategy that bridges venture and later-stage private equity. While it participates in growth financing, it has the capacity to lead buyouts, take-private transactions, and complex recapitalizations. This gives portfolio companies a single capital source that can support them from an initial $20 million minority growth investment through to a full control acquisition, avoiding the traditional handoff between early-stage VCs and later-stage buyout funds.

### In which geographies does MVM Partners invest?

MVM pursues a global investment outlook focused primarily on North America and Europe. With offices in London, Boston, and the San Francisco Bay Area, the firm targets companies that operate in or intend to scale across large addressable markets in these regions. The firm does not highlight Asia or other emerging markets as a core deployment focus based on its current disclosed portfolio and team footprint.

### What types of healthcare sectors does MVM explicitly avoid?

MVM does not publish a list of excluded sectors, but its investment focus areas—medical devices, pharmaceuticals, diagnostics, digital health, health IT, and life science tools—indicate a concentration on regulated, high-barrier markets. The firm does not mention services such as hospital operations, nursing homes, or general healthcare staffing as part of its core strategy.

## Related profiles

- [MVI Advisors](https://altss.com/profile/mvi-advisors)
- [MVolution Partners](https://altss.com/profile/mvolution-partners)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/mvm-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology